Pre-Exposure Prophylaxis (PrEP): What Anesthesia Providers need to know about this Important HIV Prevention Tool-Pre-Exposure Prophylaxis( PrEP): What Anesthesia Providers Need to Know about this Important HIV Prevention Tool

Pre-Exposure Prophylaxis( PrEP): What Anesthesia Providers Need to Know about this Important HIV Prevention Tool

Video Transcription

Video Summary

In a recent session, Jeff Darna, a member of the American Association of Nurse Anesthesiology's Professional Development Committee, provided crucial administrative updates. These included reminders about using the association’s app for notes and questions, and the importance of completing session evaluations by the deadline of September 9, 2024, to claim CEUs. Additionally, abstracts for next year can be submitted starting August 14.<br /><br />Dr. Jennifer Bajamdar and Jake Forrester presented on post-exposure prophylaxis (PrEP) for HIV prevention, focusing on its significance, pharmacology, and implications for anesthesia providers. Bajamdar and Forrester elaborated on various PrEP medications like Truvada, Dyscovi, and the injectable Apertude, explaining their mechanisms, administration, and effectiveness. They highlighted the necessity of continuing PrEP during the perioperative period to maintain its efficacy and addressed the absence of specific anesthesia medication contraindications with PrEP.<br /><br />The session also tackled the barriers and stigma associated with PrEP usage, emphasizing the importance of reducing stigma to ensure patients feel comfortable disclosing their treatment. The presenters called for more research on PrEP's long-term safety and its interactions with anesthesia medications, aiming to foster better clinical practices and patient support.

Keywords

Jeff Darna

American Association of Nurse Anesthesiology

Professional Development Committee

CEUs

PrEP

HIV prevention

Truvada

Dyscovi

Apertude